Experimental combo targets Hard-to-Treat bone cancer
NCT ID NCT06438783
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to standard treatments. The study aimed to see if the combination was safe and could slow cancer growth. However, the trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing cancer hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing jishuitan hospital
Beijing, Beijing Municipality, 100035, China
-
Hunan cancer hospital
Changsha, Hunan, 410031, China
-
Pekjing university people's hospital
Beijing, Beijing Municipality, 100044, China
-
Tianjin medical university cancer institute&hospital
Tianjin, Tianjin Municipality, 300181, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB2928 injection (a lab-made antibody targeting CD47) plus anlotinib hydrochloride capsule (a cancer drug that blocks blood vessel growth)
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced osteosarcoma or other solid tumors that have stopped responding to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 20 participants, so results may not apply to larger groups. The trial was terminated early, and the combination may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.